Overall, these studies identify the biomechanical phenotype as a targetable vulnerability of BRAF-mutated melanoma exposed to MAPK therapeutics, and reveal that preventing the pro-fibrotic stromal reaction in response to TT is a viable therapeutic option to overcome non-genetic adaptive drug resistance. The gene discussed is BRAF; the disease is melanoma.